# FDA 483 - Aurobindo Pharma Limited - February 10, 2026

Source: https://www.keypedia.com/records/483/aurobindo-pharma-limited/fa93be5a-0031-4676-b411-4813d0c7f1aa

> FDA 483 for Aurobindo Pharma Limited on February 10, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Aurobindo Pharma Limited
- Inspection Date: 2026-02-10
- Product Type: drugs
- Office Name: Office of Inspections and Investigations
- Summary: An FDA Form 483 was issued to Aurobindo Pharma Limited, Unit VII, detailing multiple deficiencies in their manufacturing and quality control processes. Observations included issues with equipment cleaning, computer system controls, master production records, complaint handling, and investigation of discrepancies. The report indicates a need for significant improvements in quality systems and adherence to CGMP requirements.

## Related Documents

- [483 - 2019-09-27](https://www.keypedia.com/records/483/aurobindo-pharma-limited/7bfb2b5e-0991-4dcb-861b-ef0d934ade3d)
- [483 - 2022-05-10](https://www.keypedia.com/records/483/aurobindo-pharma-limited/32976071-2001-4f14-887c-76d96e0a30e8)
- [483 - 2022-05-10](https://www.keypedia.com/records/483/aurobindo-pharma-limited/cdc2cd57-b94d-4778-9f26-a81d8d0d6db3)
- [483 - 2026-01-28](https://www.keypedia.com/records/483/aurobindo-pharma-limited/4402f9cb-7684-4577-a119-d85aa7d6b1c3)

## Related Officers

- [Pratik S. Upadhyay](https://www.keypedia.com/people/pratik-s-upadhyay/22ff2e0b-17d4-4c91-a3f0-c7e30b7a115b)
- [Nibin Varghese](https://www.keypedia.com/people/nibin-varghese/43e17f63-2c1f-4d46-b26f-dc8ac8885438)
- [Investigator](https://www.keypedia.com/people/guerlain-ulysse/aeef6f71-43b1-4116-b563-8bb3f2966d6a)

Company: https://www.keypedia.com/companies/aurobindo-pharma-limited/95bcc3b3-09a1-4249-af2f-5c83de789b76

Office: https://www.keypedia.com/offices/office-of-inspections-and-investigations/7dd0b904-a3df-46bc-a7b2-70ddb6f809c8